98%
921
2 minutes
20
Atrial fibrillation is the most common arrhythmia and is associated with high morbidity and mortality from stroke, heart failure, myocardial infarction, and cerebral thrombosis. Effective and rapid detection of atrial fibrillation is critical to reducing morbidity and mortality in patients. Screening atrial fibrillation quickly and efficiently remains a challenging task. In this paper, we propose SS-SWT and SI-CNN: an atrial fibrillation detection framework for the time-frequency ECG signal. First, specific-scale stationary wavelet transform (SS-SWT) is used to decompose a 5-s ECG signal into 8 scales. We select specific scales of coefficients as valid time-frequency features and abandon the other coefficients. The selected coefficients are fed to the scale-independent convolutional neural network (SI-CNN) as a two-dimensional (2D) matrix. In SI-CNN, a convolution kernel specifically for the time-frequency characteristics of ECG signals is designed. During the convolution process, the independence between each scale of coefficient is preserved, and the time domain and the frequency domain characteristics of the ECG signal are effectively extracted, and finally the atrial fibrillation signal is quickly and accurately identified. In this study, experiments are performed using the MIT-BIH AFDB data in 5-s data segments. We achieve 99.03% sensitivity, 99.35% specificity, and 99.23% overall accuracy. The SS-SWT and SI-CNN we propose simplify the feature extraction step, effectively extracts the features of ECG, and reduces the feature redundancy that may be caused by wavelet transform. The results shows that the method can effectively detect atrial fibrillation signals and has potential in clinical application.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251457 | PMC |
http://dx.doi.org/10.1155/2020/7526825 | DOI Listing |
Lancet Digit Health
September 2025
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; NIHR Biomedical Research Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Background: New-onset atrial fibrillation, a condition associated with adverse outcomes in the short and long term, is common in patients admitted to intensive care units (ICUs). Identifying patients at high risk could inform trials of preventive interventions and help to target such interventions. We aimed to develop and externally validate a prediction model for new-onset atrial fibrillation in patients admitted to ICUs.
View Article and Find Full Text PDFHeart
September 2025
Department of Cardiology, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.
Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.
Europace
September 2025
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Thromb Haemost
September 2025
Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Background: Atrial fibrillation (AF) is the most common arrhythmia in adults, with incidence increasing with age. Cognitive impairment (CoI) and dementia share risk factors with AF. Meta-analyses indicate that AF increases the risk of CoI by 2.
View Article and Find Full Text PDFJ Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.